Integrating new targeted agents into the treatment of non-small-cell lung cancer

Lung Cancer

Volumn 54, Issue SUPPL. 2, 2006, Pages

  Thatcher, Nick ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Cetuximab; Chemotherapy; EGFR; Erlotinib; Gefitinib; NSCLC; Pemetrexed; Targeted

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE;

ARTICLE; BLEEDING; CANCER STAGING; CLINICAL TRIAL; DRUG EFFICACY; GENE TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 33750627160     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.09.012     Document Type: Article

References (36)

1. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
3. Gridelli C., Rossi A., and Maione P. New antiangiogenetic agents and non-small cell lung cancer. Crit Rev Oncol Hematol (2006) [Epub ahead of print]
4. Sandler A.B., Gray R., Brahmer J., Dowlati A., Schiller J.H., Perry M.C., et al. Randomised phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small-cell lung cancer (NSCLC): an Easter Cooperative Oncology Group (ECOG) trial-E4599. J Clin Oncol 23 16S (2005) LBA4 [Abstract]
5. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 184-191
6. Thienelt C.D., Bunn Jr. P.A., Hanna N., Rosenberg A., Needle M.N., Long M.E., et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23 (2005) 786-793
7. Scagliotti G.V., Selvaggi G., Novello S., and Hirsch F.R. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10 (2004) S32-S42
8. Noonberg S.B., and Benz C.C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59 (2000) 753-767
9. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 (2003) 2237-2246
10. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
11. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
12. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
13. Gatzemeier U., Heller A., Foernzler D., Moecks J., Ward C., de Rosa F., et al. Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT). J Clin Oncol 23 (2005) 7028 [Abstract]
14. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
15. Bepler G., Williams C.C., Chiappori A., Antonia S.J., Haura E.B., Mahany J.J., et al. Docetaxel and gefitinib in the first-line treatment of elderly patients (70) with advanced non-small cell lung cancer (ANSCLC): results of phase II trial. J Clin Oncol 23 16S (2005) 7155 [Abstract]
16. Robert F., Blumenschein G., Herbst R.S., Fossella F.V., Tseng J., Saleh M.N., et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 9089-9096
17. Gumerlock P.H., Pryde B.J., KimuraI T., Galvin V., Scott S.L., Mack P.C., et al. Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 22 (2003) 662 [Abstract]
18. Davies A.M., Lara P.N., Lau D.H., Mack P.C., Gumerlock P.H., and Gandara D.R. Intermittent erlotinib in combination with docetaxel (DOC): phase I schedules designed to achieve pharmacodynamic separation. J Clin Oncol 23 16S (2005) 7038 [Abstract]
19. Rosell R., Daniel C., Ramlau R., Szczesna A., Constenla M., and Mennecier B. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 23 16S (2005) 7012 [Abstract]
20. Miller V.A., Hirsch F.R., and Johnson D.H. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol 23 (2005) 3288-3293
21. West H.L., Franklin W.A., McCoy J., Gumerlock P.H., Vance R., Lau D.H., et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 24 (2006) 1807-1813
22. Jackman D., Lucca J., Fidias P., Rabin M.S., Lynch T.J., Ostler P., et al. Phase II study of the EGFR tyrosine kinase erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma. J Clin Oncol 23 16S (2005) 7148 [Abstract]
23. Giaccone G., Lechevalier T., Thatcher N., Smit E., Janmaat M., Rodriguez J., et al. A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer. J Clin Oncol 23 16S (2005) 7073 [Abstract]
24. Lilenbaum R., Axerold R., Thomas S., Dowlati A., Seigel L., Albert D., et al. Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. J Clin Oncol 24 18S (2006) 7022 [abstract]
25. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
26. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
27. Blackhall F., Ranson M., and Thatcher N. Where next for gefitinib in patients with lung cancer?. Lancet Oncol 7 (2006) 499-507
28. Johnson J.R., Cohen M., Sridhara R., Chen Y.F., Williams G.M., Duan J., et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11 (2005) 6414-6421
29. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23 (2005) 2556-2568
30. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
31. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
32. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
33. The TAX 320 Non-Small Cell Lung Cancer Study Group, Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18 (2000) 2354-2362
34. Cufer T., Vrdoljak E., Gaafar R., Erensoy I., and Pemberton K. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 17 (2006) 401-409
35. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
36. Fehrenbacher L., O'Neill V., Belani C.P., Bonomi P., Hart L., Melnyk O., et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 24 18S (2006) 7062 [Abstract]